SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YEEHAW CANDIDATES
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Galirayo who wrote (10192)8/2/2005 7:35:56 PM
From: Raj Ramaswamy  Read Replies (1) of 23958
 
05:14 ET ViroPharma beats by 2 cents; raises 2005 guidance (VPHM) :Reports Q2 (Jun) earnings of $0.11 per share, $0.02 better than the Reuters Estimates consensus of $0.09; revenues rose 1542.1% year/year to $29.0 mln vs the $26.6 mln consensus. Net sales of Vancocin were a record $28.8 mln for Q2. For 2005, co expects net product sales of $100-$105 mln, representing growth of 85-94% over unaudited net product sales of Vancocin in 2004; expects net cash flows provided by operations of at least $40 mln.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News